Abstract: Triiodoallyl- or iodopropargyl-substituted tetrazole compounds which are prepared by reacting substituted tetrazole compound with reactive derivatives of corresponding triiodoallyl alcohol or iodopropargyl alcohol or by iodinating propargyltetrazole compounds, as well as antibacterial and antifungal compositions for medicinal, agricultural and industrial fields which contain as active ingredient said tetrazole compounds.

Abstract: The subject invention includes a 1-oxa-1-dethia-cephalosporin compound represented by the general formula (1) ##STR1## wherein R.sup.1 is a group of the formula: ##STR2## where R.sup.5 is a methyl group, an ethyl group, a carboxymethyl group or a 2-carboxy isopropyl group, or R.sup.1 is a group of the formula: ##STR3## where R.sup.6 is a hydrogen atom, a 4-ethyl-2,3-dioxopiperazine-1-yl group, a 3,4-dihydroxy phenyl group or a 5- and 6-membered heterocyclic radical having 2 ring nitrogens as the sole hetero substituent in the ring and having at least one hetero group on the carbon adjacent to the ring nitrogens.

Abstract: Triiodoallyl- or iodopropargyl-substituted heterocyclic aromatic compounds which can be prepared by reacting unsubstituted- or substituted nitrogen-containing heterocyclic compounds with corresponding iodine containing alcohol reactive derivatives in the presence of a base in an inert organic solvent. These new heterocyclic aromatic compounds have remarkable antibacterial and antifungal activities and are useful as antibacterial and antifungal agents in medicinal, agricultural and industrial fields.

Abstract: Disclosed is a process for preparing antibiotic 1-oxadethiacephalosporins via diazo-species I: ##STR1## wherein: A is acyl; R.sup.1 is H or OCH.sub.3 ; and R.sup.2 is a protecting group.

Abstract: This invention relates to 1-oxa-1-dethia-cephalosporins which are useful as anti-biotics.

Abstract: Disclosed is a novel process for preparing [(3-amino-3-carboxy)-propyl-1]phosphinic acid derivatives, comprising reacting an alkylalkylphosphonyl halide with a vinylmagnesium halide to form a vinylphosphinic acid derivative, and reacting the vinylphosphinic acid derivative with a Shiff's base to form the aimed product. Also disclosed is a novel intermediate compound formed during the course of the above process, which compound has the general formula: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification).

Abstract: Disclosed is a novel process for optically active [(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives, which comprises reacting a Shiff's base with a derivative of vinylphosphinate in the presence of a base, and subjecting the resulting compound to hydrolysis to form the optically active [(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives as either [L-(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives or [D-(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives.

Abstract: New 1-Oxadethiacephalosporins having a 3-loweralkyl thio group, and antibacterial compositions containing the same.

Abstract: Disclosed is a process for preparing antibiotic 1-oxadethiacephalosporins via diazo-species I: ##STR1## wherein: A is acyl; R.sup.1 is H or OCH.sub.3 ; and R.sup.2 is a protecting group.

Abstract: Disclosed are compounds having the following general formula: ##STR1## wherein n is an integer of 1 or 2; R.sup.1 is an amino group when n is 2, or an amino group or a hydroxyl group when n is 1; and R.sup.2 is a hydroxyl group when n is 1, or a hydroxyl group or a group of the formula ##STR2## when n is 2; and microbiological process for producing the same. The compounds are useful as precursors for raising the production rate of SF-1293 substance. Some of the compounds are also useful as intermediates for synthesis of 2-amino-4-(hydroxy)(methyl)phosphinoylbutyric acid and the SF-1293 substance.

Abstract: 2-Amino-4-(hydroxy)phosphinoylbutyryl-L-alanyl-L-alanine.

Abstract: A new polymeric compound, MF-300, is provided, which possesses a specific protective activity against bacterial infections caused particularly by Pseudomonas aeruginosa. The compound is derived from the reaction of ribostamycin with crotonoyl chloride followed by concentration of the reaction product and by subsequent recovery therefrom of a fraction having a range of molecular weights of 10,000.about.100,000 when measured by ultrafiltration method.

Abstract: Novel cephalosporin derivatives having formulae (V) and (III): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.8 and A are defined as in the specification.

Abstract: 5-Substituted picolinic acid derivatives represented by the formula (I): ##STR1## wherein R.sub.1 represents a straight or branched chain halogen-substituted alkyl group having 2 to 6 carbon atoms or a substituted phenyl group having the formula ##STR2## wherein R.sub.3 and R.sub.4, which may be the same or different, each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group, an N-alkyl-substituted amino group, an acylamino group, an acetyl group, an acyloxy group, a hydroxy group or a halogen-substituted alkyl group or R.sub.3 and R.sub.4, when taken together, represent a polymethylene chain; and R.sub.

Abstract: 5-Alkoxy-picolinic esters represented by the formula (I): ##STR1## wherein R represents an alkyl group having 1 to 6 carbon atoms and R.sub.1 represents an unsubstituted phenyl group; a phenyl group substituted with one or more of an alkyl group having 1 to 4 carbon atoms or an acetyl group; a phthalidyl group; an alkoxyalkyl group wherein the alkyl moiety and the alkoxy moiety each has 1 to 4 carbon atoms; an alkoxyalkoxyalkyl group wherein the alkyl moiety and the alkoxy moiety each has 1 to 4 carbon atoms; an indanyl group; or an acyloxyalkyl group having the formula ##STR2## wherein R.sub.2 represents a hydrogen atom or a methyl group and R.sub.3 represents an alkyl group having 1 to 5 carbon atoms (such as a methyl, n-propyl, isobutyl, t-butyl, etc.

Abstract: 5-Alkoxy-picolinic acids and the salts and the esters thereof represented by the formula (I): ##STR1## wherein R represents an alkyl group having 1 to 6 carbon atoms and M represents a hydrogen atom; a calcium atom; a sodium atom; a potassium atom; an aluminum atom; an unsubstituted phenyl group; a phenyl group substituted with one or more of an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or a halogen atom (such as a chlorine, bromine, iodine, etc., atom); a phthalidyl group; an alkoxyalkyl group wherein the alkyl moiety and the alkoxy moiety each has 1 to 4 carbon atoms; or an acyloxyalkyl group having the formula ##STR2## wherein R.sub.2 represents a hydrogen atom or a methyl group and R.sub.3 represents an alkyl group having 1 to 5 carbon atoms (such as a methyl, n-propyl, isobutyl, t-butyl, etc.

Abstract: A novel antibiotic substance SF-1540 and a process for preparing the same which comprises culturing a substance SF-1540-producing microorganism belonging to the genus Streptomyces in a medium and isolating and recovering the substance SF-1540 from a cultured broth; a novel derivative of the substance SF-1540 and a process for preparing the same which comprises treating said antibiotic substance SF-1540 with methanol to form the corresponding antibiotic substance SF-1540 derivative.

Abstract: A new antibiotic SF-1771 substance is produced by cultivating a new strain, Streptomyces toyocaensis SF-1771, in a liquid culture medium under aerobic conditions. This antibiotic may be isolated from the fermentation broth by treating the broth filtrate with a synthetic adsorbent resin for adsorption of the active compound and eluting the resin with an aqueous alcohol or aqueous acetone, followed by chromatographic purification. SF-1771 substance is a copper-containing antibiotic which shows antibacterial activity against Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis. Removal of the copper component from SF-1771 substance by treatment with hydrogen sulfide, an alkali metal sulfide or a copper-chelating agent gives SF-1771-B substance containing no copper component which shows antibacterial activity as high as but a toxicity lower than SF-1771 substance.

Abstract: New antibiotics SF-1130-x.sub.1 substance and SF-1130-x.sub.2 substance are produced by cultivating a microorganism Streptomyces myxogenes SF-1130 now deposited under FERM-P. 676 and ATCC. 31305 in a liquid culture medium under aerobic conditions, and these antibiotics may be isolated from the fermentation broth and are useful as an activator for enhancing the host defense system in living animals. The activity of these antibiotics may be improved when used in combination with one or more of maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose and maltoheptaose.

Abstract: Novel compounds useful as hypotensive agents are presented having the general formula I ##STR1## wherein R.sub.1 represents a substituted or unsubstituted aralkyl group, that is an aralkyl group of the general formula ##STR2## wherein R.sub.2 represents hydrogen, a lower alkyl group or a halogen atom. Furthermore, new therapeutic compositions of matter are also described incorporating the above novel 3-substituted-2(1H)pyridone-6-carboxylic acids (I) as an active ingredient with carriers and showing uses as hypotensive agents. These new compounds of the formula I are prepared by reacting D-glucaro-.delta.-lactam or its salt with an aralkyl halide.